Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
Date:1/21/2011

and metastasis," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals.  "CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumor cancers in that its unique mechanism of action disrupts the signaling of specific protein to protein binding between FAK and tumors."

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options.

About Focal Adhesion Kinase (FAK)Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.  

About CureFAKtor PharmaceuticalsCureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer. CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute.  CureFAKtor is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemothera
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. Amylin Pharmaceuticals to Webcast Year-End Financial Results
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
5. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
6. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
7. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
8. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
10. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
11. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... MINNEAPOLIS, Oct. 29 The Minnesota State High School ... have teamed up to make the Minnesota State High School tournaments ... MSHSL has purchased eight mobile Automated External Defibrillators (AED) from HeartSine ... Cardiac Arrest (SCA), which is the leading cause of death in ...
... This holiday season, settle your stomach, relieve your wallet ... holidays, when many of us may suffer from occasional heartburn, a ... finds that you probably don,t need an expensive drug like Nexium, ... uses comparative effectiveness research to identify "Best Buys" based on safety, ...
Cached Medicine Technology:Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses ... long evening dresses . All the company’s old ... current discount is up to 66 percent off. ... the fashion field. Its dress specialists are striving to ... parts of the world. All the company’s items are ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
(Date:10/19/2014)... The federal litigation involving GranuFlo ... forward in Massachusetts federal court, where more than ... dialysis medication, Bernstein Liebhard LLP reports. , ... 2,127 claims now filed over GranuFlo and NaturaLyte ... District Court, District of Massachusetts. Plaintiffs in these ...
(Date:10/19/2014)... DENVER (October 20, 2014) - As Alaska ... the outright legalization of recreational marijuana for adults, Ryan ... in those states and elsewhere in America: make sure ... chaos. , Fox is founder and CEO of The ... first recreational dispensaries. , The Grass Station also ...
(Date:10/19/2014)... October 19, 2014 According to the ... the vast majority of adults (up to 90 ... in their lives, spending at least $50 billion on ... includes; spinal instability, stenosis, spondylolisthesis, and symptomatic degenerative disc ... wear and tear associated with the aging process, but ...
Breaking Medicine News(10 mins):Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 2Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 5
... a special protein responsible for cell development (Notch) ... new study shows. ,“Breast cancer cells ... by commonly used hormonal therapy, by increasing the ... Miele, professor, departments of pathology, pharmacology and experimental ...
... basis of recent studies that the commonly employed //chemotherapy ... ,AC/T, a widely accepted chemotherapy might be ... which has been proven to be more efficient in ... also has been proven to be far superior to ...
... doctoral thesis from Karolinska Institutet, our everyday environments are ... degrees when inhaled. Particularly damaging to our cellular DNA ... Sweden. ,"Luckily, most of them do ... time," says scientist Hanna Karlsson. "However, particle levels are ...
... developed a new anti-aging ingredient known as GGC, which ... early next year. // ,GGC is a precursor ... a broad range of potential health benefits. Glutathione is ... in cancer, diabetes, aging and other diseases and degenerative ...
... Madhya Pradesh took part in an AIDS awareness campaign and ... ,The students tied 'suraksha bandhan' (protection bands) on ... their commitment to spread this awareness. ,The students ... of Journalism here as part of a 'Unite for Children, ...
... frozen ready meals including 20 Asda own brand, 4 Sainsbury’s ... may contain small pieces of glass. Customers are also being ... ,The products came from Rye Valley Foods in Carrickmacross, a ... the country's biggest food processors. The company said pieces of ...
Cached Medicine News:Health News:Study Identifies Mechanism Which May Help Tamoxifen Work Better 2Health News:Underground Air - Associated With - DNA Damages 2
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: